Sun Pharma Advanced Research Company responded to BSE's surveillance query on unusual volume increase in its scrip.
SPARC confirmed full compliance with Regulation 30 of SEBI LODR Regulations 2015, with all required disclosures made.
Company stated no undisclosed price-sensitive information exists and reaffirmed commitment to timely exchange disclosures.